{"id":128,"date":"2024-12-08T11:59:28","date_gmt":"2024-12-08T11:59:28","guid":{"rendered":"https:\/\/upnifty.com\/apps\/?ipo=sai-life-sciences-limited-ipo"},"modified":"2024-12-08T11:59:28","modified_gmt":"2024-12-08T11:59:28","slug":"sai-life-sciences-limited-ipo","status":"publish","type":"ipo","link":"https:\/\/upnifty.com\/apps\/ipo\/sai-life-sciences-limited-ipo\/","title":{"rendered":"Sai Life Sciences Limited IPO"},"content":{"rendered":"


\n<\/p>\n

\n

About Sai Life Sciences IPO<\/h2>\n

\n

Sai Life Sciences IPO is a book-built issue aiming to raise \u20b93,042.62 crore. It includes a fresh issue of 1.73 crore shares worth \u20b9950.00 crore and an offer for sale of 3.81 crore shares amounting to \u20b92,092.62 crore.\u00a0<\/span><\/p>\n

The IPO opens for subscription on December 11, 2024, and closes on December 13, 2024. Allotment is expected on December 16, 2024, with the listing anticipated on December 18, 2024, on both the BSE and NSE.<\/span><\/p>\n

The IPO price band is set at \u20b9522 to \u20b9549 per share, with a minimum lot size of 27 shares. Retail investors need a minimum investment of \u20b914,823. For non-institutional investors, small NII can invest in 14 lots (378 shares) worth \u20b92,07,522, while large NII require 68 lots (1,836 shares) amounting to \u20b91,007,964.<\/span><\/p>\n

Kotak Mahindra Capital, Jefferies India, Morgan Stanley India, and IIFL Securities are the book-running lead managers. Kfin Technologies Limited is the registrar for the issue. Investors can refer to the Sai Life Sciences IPO RHP for detailed information about the offering.<\/span><\/p>\n

Industry Outlook<\/strong><\/h2>\n
    \n
  1. The global pharmaceutical market, valued at USD 1,451 billion in 2023, is expected to grow at a CAGR of 6.2% to reach USD 1,956 billion by 2028. This growth is driven by factors like an aging population, rising chronic diseases, and increased health consciousness.\u00a0<\/span><\/li>\n
  2. India’s Contract Research, Development, and Manufacturing Organisation (CRDMO) industry is projected to grow by 14% annually, from USD 7.3 billion in 2023 to USD 14.1 billion by 2028.<\/span><\/li>\n
  3. The pre-clinical development segment in India’s CRDMO industry is expected to grow at a CAGR of 15.7% from FY23 to FY28. This growth is driven by enhanced R&D capabilities in India.<\/span><\/li>\n<\/ol>\n

    Sai Life Sciences IPO Objectives\u00a0<\/strong><\/h2>\n

    The company plans to allocate the net proceeds from the issuance to the following purposes:<\/span><\/p>\n

      \n
    1. The funds will be used to repay or prepay outstanding borrowings, either in full or part, reducing the company\u2019s debt burden.<\/span><\/li>\n
    2. The remaining funds will be allocated towards general corporate purposes.<\/span><\/li>\n<\/ol>\n

      About Sai Life Sciences Limited\u00a0<\/strong><\/h2>\n

      Sai Life Sciences Limited is a leading Contract Research, Development, and Manufacturing Organisation (CRDMO) that provides comprehensive services across the drug discovery, development, and manufacturing value chain. The company serves global pharmaceutical and biotechnology firms, offering both contract research (CRO) and contract development and manufacturing (CDMO) capabilities.\u00a0<\/span><\/p>\n

      With a strong presence in key global markets, Sai Life Sciences has become one of the fastest-growing Indian CRDMOs, driven by a 117% growth in its commercial and late-stage product portfolio since 2019. The company operates research laboratories in major innovation hubs like Boston (US) and Manchester (UK), complemented by large-scale facilities in India, enabling cost-effective solutions for drug discovery and manufacturing.\u00a0<\/span><\/p>\n

      As of September 30, 2024, Sai Life Sciences had served over 280 pharmaceutical companies, including 18 of the top 25 global pharma companies. Its portfolio includes over 170 innovator pharmaceutical products, with several drugs approved and commercially available.<\/span><\/p>\n

      Sai Life Sciences is committed to sustainability, incorporating energy-saving measures, increasing the use of renewable energy, and reducing carbon emissions. The company is also a member of the Pharmaceutical Supply Chain Initiative (PSCI) and has received a silver rating for sustainability by EcoVadis.\u00a0<\/span><\/p>\n

      Peer Details<\/strong><\/h2>\n

      According to RHP, the following are the listed peers of Sai Life Sciences Limited:<\/span><\/p>\n

        \n
      1. Divi’s Laboratories Limited<\/span><\/li>\n
      2. Suven Pharmaceuticals Limited<\/span><\/li>\n
      3. Syngene International Limited<\/span><\/li>\n<\/ol>\n

        How To Check the Allotment Status of the Sai Life Sciences IPO?<\/strong><\/h2>\n

        Steps to check IPO allotment status on Angel One\u2019s app:<\/span><\/p>\n

          \n
        1. Log in to the Angel One app.<\/span><\/li>\n
        2. Go to the IPO Section and then to IPO Orders.<\/span><\/li>\n
        3. Select the individual IPO that you had applied for and check the allotment status.<\/span><\/li>\n
        4. Angel One will notify you of your IPO allotment status via push notification and email.<\/span><\/li>\n<\/ol>\n

          How to apply for Sai Life Sciences IPO online?<\/strong><\/h2>\n
            \n
          1. Login to Your Angel One Account: <\/strong>Open the Angel One app or website and log in with your credentials.<\/span><\/li>\n
          2. Locate the IPO Section: <\/strong>Navigate to the ‘IPO’ section on the platform.<\/span><\/li>\n
          3. Select IPO: <\/strong>Find and select the Sai Life Sciences IPO from the list of open IPOs.<\/span><\/li>\n
          4. Enter the Lot Size: <\/strong>Specify the number of lots you want to bid for.<\/span><\/li>\n
          5. Submit Your UPI ID: <\/strong>Enter your UPI ID to link your payment method and submit your application.<\/span><\/li>\n
          6. Approve Funds: <\/strong>Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.<\/span><\/li>\n<\/ol>\n

            Contact Details of Sai Life Sciences IPO\u00a0<\/strong><\/h2>\n

            Registered office:<\/strong> Plot No. DS-7,IKP Knowledge Park, Turkapally Village, ShameerpetMandal, Medchal\u2013Malkajgiri District, Hyderabad 500078, Telangana, India<\/span><\/p>\n

            Phone: <\/strong>+9140 6815 6000<\/span><\/p>\n

            E-mail: <\/strong>investors@sailife.com<\/span><\/a>\u00a0<\/span><\/p>\n

            Sai Life Sciences IPO Reservation<\/strong><\/h2>\n\n\n\n\n\n\n
            \n

            Investor Category<\/strong><\/p>\n<\/td>\n

            		\n

            Shares Offered<\/strong><\/p>\n<\/td>\n<\/tr>\n

            \n

            QIB Shares Offered<\/span><\/p>\n<\/td>\n

            		\n

            Not more than 50.00% of the Net offer<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            Retail Shares Offered<\/span><\/p>\n<\/td>\n

            		\n

            Not less than 35.00% of the Net Issue<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            NII (HNI) Shares Offered<\/span><\/p>\n<\/td>\n

            		\n

            Not less than 15.00% of the Net Issue<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

            Sai Life Sciences IPO Lot Size<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
            \n

            Application<\/strong><\/p>\n<\/td>\n

            		\n

            Lots<\/strong><\/p>\n<\/td>\n

            		\n

            Shares<\/strong><\/p>\n<\/td>\n

            		\n

            Amount<\/strong><\/p>\n<\/td>\n<\/tr>\n

            \n

            Retail (Min)<\/span><\/p>\n<\/td>\n

            		\n

            1<\/span><\/p>\n<\/td>\n

            		\n

            27<\/span><\/p>\n<\/td>\n

            		\n

            \u20b914,823<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            Retail (Max)<\/span><\/p>\n<\/td>\n

            		\n

            13<\/span><\/p>\n<\/td>\n

            		\n

            351<\/span><\/p>\n<\/td>\n

            		\n

            \u20b91,92,699<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            HNI (Min)<\/span><\/p>\n<\/td>\n

            		\n

            14<\/span><\/p>\n<\/td>\n

            		\n

            378<\/span><\/p>\n<\/td>\n

            		\n

            \u20b92,07,522<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            S-HNI (Max)<\/span><\/p>\n<\/td>\n

            		\n

            67<\/span><\/p>\n<\/td>\n

            		\n

            1,809<\/span><\/p>\n<\/td>\n

            		\n

            \u20b99,93,141<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            B-HNI (Min)<\/span><\/p>\n<\/td>\n

            		\n

            68<\/span><\/p>\n<\/td>\n

            		\n

            1,836<\/span><\/p>\n<\/td>\n

            		\n

            \u20b910,07,964<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

            Sai Life Sciences IPO Promoter Holding<\/strong><\/h2>\n

            The company’s promoters include Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners, and Tulip Partners.<\/span><\/p>\n\n\n\n\n
            \n

            Share Holding Pre-Issue<\/strong><\/p>\n<\/td>\n

            		\n

            40.48%<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            Share Holding Post Issue<\/strong><\/p>\n<\/td>\n

            		\n

            _<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

            Key Performance Indicators for Sai Life Sciences IPO<\/strong><\/h2>\n

            The Sai Life Sciences IPO has a market capitalisation of \u20b911,418.63 crore as of March 31, 2024.<\/span><\/p>\n\n\n\n\n\n\n\n\n
            \n

            KPI<\/strong><\/p>\n<\/td>\n

            		\n

            Value<\/strong><\/p>\n<\/td>\n<\/tr>\n

            \n

            ROE<\/strong><\/p>\n<\/td>\n

            		\n

            11.79%<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            ROCE<\/strong><\/p>\n<\/td>\n

            		\n

            15.96%<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            RoNW<\/strong><\/p>\n<\/td>\n

            		\n

            8.13%<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            P\/BV<\/strong><\/p>\n<\/td>\n

            		\n

            10.18<\/span><\/p>\n<\/td>\n<\/tr>\n

            \n

            PAT Margin (%)<\/strong><\/p>\n<\/td>\n

            		\n

            5.65<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

            Sai Life Sciences IPO Prospectus<\/strong><\/h2>\n